SEPSIS UPDATE 2013 David Willms MD FCCP FCCM Sharp Memorial Hospital.
IMPROVING OUR UNDERSTANDING OF DRUG ASSOCIATED AKI Sandra Kane-Gill, PharmD, MS, FCCM, FCCP...
-
Upload
caitlin-wilkerson -
Category
Documents
-
view
217 -
download
0
Transcript of IMPROVING OUR UNDERSTANDING OF DRUG ASSOCIATED AKI Sandra Kane-Gill, PharmD, MS, FCCM, FCCP...
![Page 1: IMPROVING OUR UNDERSTANDING OF DRUG ASSOCIATED AKI Sandra Kane-Gill, PharmD, MS, FCCM, FCCP Associate Professor of Pharmacy, Critical Care Medicine, and.](https://reader036.fdocuments.us/reader036/viewer/2022062516/56649dc95503460f94abfd28/html5/thumbnails/1.jpg)
IMPROVING OUR UNDERSTANDING OF DRUG ASSOCIATED AKI
Sandra Kane-Gill, PharmD, MS, FCCM, FCCP
Associate Professor of Pharmacy, Critical Care Medicine, and Biomedical Informatics
Center for Critical Care Nephrology
![Page 2: IMPROVING OUR UNDERSTANDING OF DRUG ASSOCIATED AKI Sandra Kane-Gill, PharmD, MS, FCCM, FCCP Associate Professor of Pharmacy, Critical Care Medicine, and.](https://reader036.fdocuments.us/reader036/viewer/2022062516/56649dc95503460f94abfd28/html5/thumbnails/2.jpg)
Prevalence of Drug Associated Acute Kidney Injury (AKI)
• 5,143 patients in 20 ICUs• 20% (74/355) associated with drugs
• ICUs at 5 hospitals• 25% (157/618) associated with drugs
• 26,269 critically ill patients in 54 hospitals in 23 countries• 19% (328/1726) associated with drugs
Brivet FG et al. Crit Care Med 1996;24:192Mehta RL et al. Kid International 2004;66:1613-1621Uchino S et al. JAMA 2005;294:813-818.
3rd-5th
![Page 3: IMPROVING OUR UNDERSTANDING OF DRUG ASSOCIATED AKI Sandra Kane-Gill, PharmD, MS, FCCM, FCCP Associate Professor of Pharmacy, Critical Care Medicine, and.](https://reader036.fdocuments.us/reader036/viewer/2022062516/56649dc95503460f94abfd28/html5/thumbnails/3.jpg)
Understanding the Potential Risk
Most Frequently Ordered Nephrotoxins
Frequency of Orders
Acetaminophen 2751
Aspirin 1935
Cefazolin 1083
Furoseminde 2085
Piperacillin/tazobactam 1258
Vancomycin 1890
• 182 drugs commonly prescribed in ICU– 23% were known nephrotoxins
• 83,970 orders for the 182 drugs in 1 year– 18,180 orders or 22% were for a nephrotoxin
Taber SS et al. Crit Care Clin 2006;357-374.
![Page 4: IMPROVING OUR UNDERSTANDING OF DRUG ASSOCIATED AKI Sandra Kane-Gill, PharmD, MS, FCCM, FCCP Associate Professor of Pharmacy, Critical Care Medicine, and.](https://reader036.fdocuments.us/reader036/viewer/2022062516/56649dc95503460f94abfd28/html5/thumbnails/4.jpg)
Drug Associated AKI: Consequences
• Approximately 50% of patients with drug associated AKI may show permanent damage
• 70% of patients with drug associated AKI have evidence of residual kidney damage
• Similar mortality rates and/or dialysis dependence to AKI of other etiologies
• Recurrent AKI episodes have worse outcomes
Grunfeld JP et al. In: Diseases of the Kidney (eds Schrier RW et al)Menon S et a. J Pediatr 2014;165:522Mehta RL et al. Kid Int 2004;66:1613Harris DG et al. J Trauma Acute Care Surg 2014;76:1397
![Page 5: IMPROVING OUR UNDERSTANDING OF DRUG ASSOCIATED AKI Sandra Kane-Gill, PharmD, MS, FCCM, FCCP Associate Professor of Pharmacy, Critical Care Medicine, and.](https://reader036.fdocuments.us/reader036/viewer/2022062516/56649dc95503460f94abfd28/html5/thumbnails/5.jpg)
Will the risk factors or model of prediction for developing AKI be upheld in the elderly population?
Will the risk factors (including nephrotoxins) or model of prediction for developing AKI be upheld in the elderly population?
![Page 6: IMPROVING OUR UNDERSTANDING OF DRUG ASSOCIATED AKI Sandra Kane-Gill, PharmD, MS, FCCM, FCCP Associate Professor of Pharmacy, Critical Care Medicine, and.](https://reader036.fdocuments.us/reader036/viewer/2022062516/56649dc95503460f94abfd28/html5/thumbnails/6.jpg)
Methods• Data were obtained from the Medical Archival Repository
System (MARS) • International Classification Diseases, 9th edition (ICD9)• Diagnosis related group (DRG) • Severity of illness (Acute Physiology Score III)• Suspected sepsis (blood culture and antibiotic in 24h of each other)• Hypotensive index• Baseline serum creatinine• Admission creatinine• Reference creatinine
• GFR (mL/min/1.73 m2) = 175 × (Scr)-1.154 × (Age)-0.203 × (0.742 if female) × (1.212 if African American) (conventional units)
• eGFR of 75ml/min/1.73m2 when baseline creatinine missing
![Page 7: IMPROVING OUR UNDERSTANDING OF DRUG ASSOCIATED AKI Sandra Kane-Gill, PharmD, MS, FCCM, FCCP Associate Professor of Pharmacy, Critical Care Medicine, and.](https://reader036.fdocuments.us/reader036/viewer/2022062516/56649dc95503460f94abfd28/html5/thumbnails/7.jpg)
Methods: Drugs• Four sources containing drug toxicity information were
searched and a list of drug related nephrotoxins was compiled • Micromedex, UpToDate, Drug-Induced Diseases Textbook, recent
publication on drug associated AKI
• Scoring system was developed to rank the drugs’ association with nephrotoxicity based on the frequency in drug information sources
• Drug considered a known nephrotoxin if found in three or four of the drug information sources (n=62)
• List of 62 categorized by common drug classes (n=8)
![Page 8: IMPROVING OUR UNDERSTANDING OF DRUG ASSOCIATED AKI Sandra Kane-Gill, PharmD, MS, FCCM, FCCP Associate Professor of Pharmacy, Critical Care Medicine, and.](https://reader036.fdocuments.us/reader036/viewer/2022062516/56649dc95503460f94abfd28/html5/thumbnails/8.jpg)
Methods• Categorized patients by various age strata
• AKI classification according to KDIGO
• Risk factor assessment completed using a multivariate logistic regression model • Impact of age• Separate assessment by age group
![Page 9: IMPROVING OUR UNDERSTANDING OF DRUG ASSOCIATED AKI Sandra Kane-Gill, PharmD, MS, FCCM, FCCP Associate Professor of Pharmacy, Critical Care Medicine, and.](https://reader036.fdocuments.us/reader036/viewer/2022062516/56649dc95503460f94abfd28/html5/thumbnails/9.jpg)
Use of Nephrotoxins in Elderly (≥ 65y.o.) Critically Ill Patients
AKI Patients (n=12,446)
ACE/ARB InhibitorVancomycinAminoglycosideOther AntibioticsCalcineurin InhibitorNSAIDsDiureticOther Nephtotoxic Drugs
![Page 10: IMPROVING OUR UNDERSTANDING OF DRUG ASSOCIATED AKI Sandra Kane-Gill, PharmD, MS, FCCM, FCCP Associate Professor of Pharmacy, Critical Care Medicine, and.](https://reader036.fdocuments.us/reader036/viewer/2022062516/56649dc95503460f94abfd28/html5/thumbnails/10.jpg)
Multivariable Regression Analyses for AKI Patients Compared to Non-AKI Patients
![Page 11: IMPROVING OUR UNDERSTANDING OF DRUG ASSOCIATED AKI Sandra Kane-Gill, PharmD, MS, FCCM, FCCP Associate Professor of Pharmacy, Critical Care Medicine, and.](https://reader036.fdocuments.us/reader036/viewer/2022062516/56649dc95503460f94abfd28/html5/thumbnails/11.jpg)
Multivariable Regression Analyses for AKI Patients Compared to Non-AKI Patients by Age Strata
![Page 12: IMPROVING OUR UNDERSTANDING OF DRUG ASSOCIATED AKI Sandra Kane-Gill, PharmD, MS, FCCM, FCCP Associate Professor of Pharmacy, Critical Care Medicine, and.](https://reader036.fdocuments.us/reader036/viewer/2022062516/56649dc95503460f94abfd28/html5/thumbnails/12.jpg)
Comparison of AUC for Elderly vs Younger (with drugs)
![Page 13: IMPROVING OUR UNDERSTANDING OF DRUG ASSOCIATED AKI Sandra Kane-Gill, PharmD, MS, FCCM, FCCP Associate Professor of Pharmacy, Critical Care Medicine, and.](https://reader036.fdocuments.us/reader036/viewer/2022062516/56649dc95503460f94abfd28/html5/thumbnails/13.jpg)
Comparison of AUC for Elderly vs Younger (no drugs)
![Page 14: IMPROVING OUR UNDERSTANDING OF DRUG ASSOCIATED AKI Sandra Kane-Gill, PharmD, MS, FCCM, FCCP Associate Professor of Pharmacy, Critical Care Medicine, and.](https://reader036.fdocuments.us/reader036/viewer/2022062516/56649dc95503460f94abfd28/html5/thumbnails/14.jpg)
Improving our Understanding of Drug Associated AKI…
• Re-examination of known nephrotoxins in the ICU• 62 medications know to cause AKI
• Evaluate the risks of developing drug associated AKI based on a combination of patient and drug factors
• Determine the combinations of drugs (proposed and known) that increase the risk for AKI
![Page 15: IMPROVING OUR UNDERSTANDING OF DRUG ASSOCIATED AKI Sandra Kane-Gill, PharmD, MS, FCCM, FCCP Associate Professor of Pharmacy, Critical Care Medicine, and.](https://reader036.fdocuments.us/reader036/viewer/2022062516/56649dc95503460f94abfd28/html5/thumbnails/15.jpg)
Cluster Randomized Trial Evaluating Stage-based Treatment for Acute Kidney Injury (CREST AKI)
• Specific Aim 1. To optimize the clinical performance of alerts generated by a clinical decision support system for the detection of AKI in patients that are 65 years and older.
• Specific Aim 2. To test whether a clinical decision support system coupled with an interdisciplinary team improves short and long-term outcomes for patients age 65 and older with AKI
• Specific Aim 3. To test the hypothesis that structured follow-up recommendations reduce long-term sequelae in 65 and older patients developing AKI.
![Page 16: IMPROVING OUR UNDERSTANDING OF DRUG ASSOCIATED AKI Sandra Kane-Gill, PharmD, MS, FCCM, FCCP Associate Professor of Pharmacy, Critical Care Medicine, and.](https://reader036.fdocuments.us/reader036/viewer/2022062516/56649dc95503460f94abfd28/html5/thumbnails/16.jpg)
Co-Investigators• John Kellum, MD• Ragi Marugan, MD• Florentina Sileanu, MS• Steven Handler, MD, PhD
![Page 17: IMPROVING OUR UNDERSTANDING OF DRUG ASSOCIATED AKI Sandra Kane-Gill, PharmD, MS, FCCM, FCCP Associate Professor of Pharmacy, Critical Care Medicine, and.](https://reader036.fdocuments.us/reader036/viewer/2022062516/56649dc95503460f94abfd28/html5/thumbnails/17.jpg)
QUESTIONS?